Rapid Dose Therapeutics Corp. partnership with McMaster University to announced the publication of the results of their collaborative research project titled "Incorporation of Loratadine-Cyclodextrin Complexes in Oral Thin Films ("OTF") for Rapid Drug Delivery" in the Journal of Pharmaceutical Sciences. This research project enabled RDT to advance its formulation capabilities by successfully utilizing a method that increases the solubility of the commonly used drug loratadine, allowing it to be effectively loaded into the QuickStripTM delivery platform.

The described method can additionally improve the organoleptic properties of the films. Loratadine, sold under the brand name Claritin, among others, is an antihistamine commonly used to treat allergic rhinitis. It undergoes liver first pass metabolism and is a prime candidate for incorporation within an OTF. The team found that by using specific types and ratios of cyclodextrins, loratadine complexes could be formed that led to great improvements in aqueous solubility and overall drug delivery performance.

The project was funded via a Collaborative Research and Development grant awarded by the Natural Sciences and Engineering Research Council of Canada along with a matching funding contribution from RDT. This publication demonstrates RDT's ability to formulate and develop new products through both its internal scientific team and through its external collaborators.